Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Luz7.0
Lutein + Zeaxanthin – Forschung
Hilft wahrscheinlich
181 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Lutein + Zeaxanthin scheint in 14 von 15 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 1998–2026 mit einer typischen Studiengröße von 530 Teilnehmenden.
Basierend auf 181 Studien · 21 Meta-Analysen · 132 RCTs · 524,010 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
14geholfen1unklar· 166 weitere ohne bewertete Effektdaten
Nach Outcome
Vision & macular healthVerbesserte Makulapigmentdichte und Sehkomfort innerhalb von 3-6 Monaten · 3-6 Monate
Hilft wahrscheinlich166 Studien
Cognitive function
Hilft wahrscheinlich51 Studien
Women's health
Überwiegend Mechanismus / Beobachtung12 Studien
Therapeutic & clinical
Überwiegend Mechanismus / Beobachtung10 Studien
Glucose & metabolic
Überwiegend Mechanismus / Beobachtung5 Studien
Skin health
Überwiegend Mechanismus / Beobachtung4 Studien
Heart & blood pressure
Überwiegend Mechanismus / Beobachtung3 Studien
Inflammation
Zu wenige bewertete Studien2 Studien
Longevity & agingErhöht das Makulapigment; Zusammenhänge mit gesundem Altern beruhen auf Beobachtungsdaten · 3-6 Monate
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 34 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
57%
über Studien hinweg
Untersuchte Personen
524k
typische Studie: 530 Personen
Stärkste Designs
153
21 gepoolt, 132 randomisiert
Zeigte Nutzen
93%
14/15 Studien
Wie lange Studien liefen
1–3 Monate
1
3+ Monate
4
Untersuchte Populationen
Adults6
AMD patients3
General population2
Age-related macular degeneration patients2
Aktives Forschungsgebiet
66 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2024
199820122026
1Macular pigment optical densityMeta-Analysen=3,189 · very large study2021
Einfach gesagt: Our objective was to determine a minimum concentration of lutein/zeaxanthin intake that is associated with a statistically significant and/or clinically important change in macular pigment optical ...
Wilson LM et al. · Advances in nutrition (Bethesda, Md.) (2021)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Our objective was to determine a minimum concentration of lutein/zeaxanthin intake that is associated with a statistically significant and/or clinically important change in macular pigment optical density (MPOD) among adults with healthy eyes.
We included 46 studies (N = 3189 participants; mean age = 43 y; 42% male).
There was no statistically significant change in MPOD among studies evaluating <5 mg/d of total lutein/zeaxanthin intake which primarily assessed dietary interventions for 3-6 mo (pooled mean difference, 0.02; 95% CI: -0.01 to 0.05).
2Dry eye syndrome symptomsSystematische Übersichtn=584 · large study2024
Einfach gesagt: Lutein supplementation may benefit DED patients by improving symptoms and tear film stability.
Chu YC et al. · International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition (2024)
Improvements were observed in subjective symptoms, with significant reductions in Ocular Surface Disease Index (OSDI) scores in some studies.
Schirmer's test and corneal-conjunctival staining results varied, with some showing significant improvements and others not.
Lutein supplementation may benefit DED patients by improving symptoms and tear film stability.
3Progression to late AMDMeta-Analysen=85,321 · very large study2022
Einfach gesagt: Taking multivitamin supplementation may not prevent the development of late AMD.
Li SS et al. · Seminars in ophthalmology (2022)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
In the network meta-analysis, we found that there was more risk of progression to late AMD in the multivitamin group than carotenoids and vitamin E groups (RR 0.45, 95% CI 0.32 to 0.65; RR 0.56, 95% CI 0.40 to 0.79; RR 0.42, 95% CI 0.26 to 0.67).
Taking multivitamin supplementation may not prevent the development of late AMD.
The nutrient of zinc and carotenoids (lutein/zeaxanthin) supplementation were associated with better improvement in VA.
4Coronary heart disease riskMeta-Analysen=387,569 · very large study2016
Einfach gesagt: Our findings suggest that higher dietary intake and higher blood concentrations of lutein are generally associated with better cardiometabolic health.
Leermakers ET et al. · The American journal of clinical nutrition (2016)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Meta-analysis showed a lower risk of coronary heart disease (pooled RR: 0.88; 95% CI: 0.80, 0.98) and stroke (pooled RR: 0.82; 95% CI: 0.72, 0.93) for the highest compared with the lowest tertile of lutein blood concentration or intake.
There was no significant association with type 2 diabetes mellitus (pooled RR: 0.97; 95% CI: 0.77, 1.22), but higher lutein was associated with a lower risk of metabolic syndrome (pooled RR: 0.75; 95% CI: 0.60, 0.92) for the highest compared with the lowest tertile.
Our findings suggest that higher dietary intake and higher blood concentrations of lutein are generally associated with better cardiometabolic health.
Einfach gesagt: Dietary intake of these carotenoids was significantly related with a reduction in risk of late AMD (RR 0·74; 95 % CI 0·57, 0·97); and a statistically significant inverse association was observed between lutein and zeaxanthin intake and neovascular AMD risk (RR 0·68; 95 % CI 0·51, 0·92).
Ma L et al. · British Journal of Nutrition (2012)
Groß Nutzen
← SchlechterKein EffektBesser →
The pooled relative risk (RR) for early AMD, comparing the highest with the lowest category of lutein and zeaxanthin intake, was 0·96 (95 % CI 0·78, 1·17).
Dietary intake of these carotenoids was significantly related with a reduction in risk of late AMD (RR 0·74; 95 % CI 0·57, 0·97).
A statistically significant inverse association was observed between lutein and zeaxanthin intake and neovascular AMD risk (RR 0·68; 95 % CI 0·51, 0·92).
7Liver disease riskSystematische Übersichtn=30 · small study2024
Einfach gesagt: However, for malignant diseases such as liver cancer, it did not show the significant effects of carotenoid supplementation.
Hu B et al. · Food & function (2024)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
Two reviewers independently scored the literature quality and extracted data, and the results were represented by the standard mean difference (SMD) with a 95% confidence interval.
Cochran Q statistics and I2 statistics were used to evaluate statistical heterogeneity (defined as significant when P < 0.05 or I2 > 50%).
However, no significant difference was observed between serum β-cryptoxanthin (SMD = 0.02, 95% CI (-0.41, 0.45), P = 0.92) and lutein/zeaxanthin (SMD = 0.62, 95% CI (-1.20, 2.45), P = 0.502).
12Photoprotective effectsSystematische Übersichtn=47 · small study2025
Einfach gesagt: Future research is necessary to determine optimal dosing and supplementation duration for intended photoprotective outcomes.
Natarelli N et al. · Journal of medicinal food (2025)
The weakest evidence exists for photoprotective effects of isolated vitamin or coenzyme Q supplementation.
Dietary supplements may promote enhanced photoprotection, although current evidence is limited by small sample size and short duration.
Supplementation with photoprotective active ingredients may be especially favorable for individuals with predisposed ultraviolet sensitivity, such as those with polymorphic light eruption.
Einfach gesagt: Long-term AREDS2 follow-up data provide the strongest clinical evidence to date that lutein/zeaxanthin reduces AMD progression compared to beta-carotene.
Chew EY et al. · JAMA Ophthalmology (2024)
Lutein/zeaxanthin substitution reduced late AMD progression compared to beta-carotene over 10-year follow-up
Risk of neovascular AMD was significantly lower in the lutein/zeaxanthin group
Participants with lower baseline dietary carotenoid intake showed the greatest benefit
Khalighi Sikaroudi M et al. · Journal of the science of food and agriculture (2021)
Subgroup analyses showed that egg consumption: (a) had a larger effect on MPOD in studies with a parallel design; and (b) increased serum lutein to a greater extent in a healthy population.
We did not detect any heterogeneity between studies.
Daily egg consumption has beneficial effects on MPOD and serum lutein is inversely associated with reduced AMD progression.
19IL-6 levelsMeta-Analysen=26 · very small study2022
Einfach gesagt: The overall results supported possible protective effects of carotenoids on inflammatory biomarkers.
Hajizadeh-Sharafabad F et al. · Critical reviews in food science and nutrition (2022)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
The random-effect model was used to analyze data and the overall effect size was computed as weighted mean difference (WMD) and corresponding 95% of confidence interval (CI).
A total of 26 trials with 35 effect sizes were included in this meta-analysis.
Also, only lycopene (WMD: ‒1.08 pg/ml, 95%CI: ‒2.03, ‒0.12, P = 0.027) led to a significant decrease in IL-6.
Einfach gesagt: These findings provide a strong molecular basis and a line of evidence that suggests carotenoid vitamin therapy may offer enhanced neuroprotective effects with therapeutic potential to function as an adjunct nutraceutical strategy for management of diabetic retinopathy.
Lem DW et al. · Nutrients (2021)
Lutein and zeaxanthin demonstrated significant protection against capillary cell degeneration and hyperglycemia-induced changes in retinal vasculature.
Observational studies indicate that depletion of xanthophyll carotenoids in the macula may represent a novel feature of DR, specifically in patients with type 2 or poorly managed type 1 diabetes.
Meanwhile, early interventional trials with dietary carotenoid supplementation show promise in improving their levels in serum and macular pigments concomitant with benefits in visual performance.